Sustained Release Innovation for HIV (SRI) (R61/R33 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No-Go decisions and year 5 funding requires submission of a pre-IND application to the FDA. 


  • Letter of Intent Due Date(s): October 30, 2018
  • Application Due Date(s): November 30, 2018
  • AIDS Application Due Date(s): November 30, 2018

RFA-AI-18-006 Expiration Date December 1, 2018

Agency Website

Amount Description

Application budgets are limited to $800,000 in direct costs per year for the R61 award phase and $1,600,000 in direct costs per year for the R33 award phase.   
The total project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.     

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Clinical Science
Medical - Translational

External Deadline

November 30, 2018